Loading
In IDH1-mutated AML, adding ivosidenib to azacitidine tripled survival, one of the largest effects ever seen in a randomised AML trial.
Event-free survival HR 0.33 (95% CI 0.16-0.69); median OS 24.0 vs 7.9 months (HR 0.44, 95% CI 0.27-0.73); CR 47% vs 15%. Stopped early for benefit. NEJM 2022. Whether ivosidenib-azacitidine or venetoclax-azacitidine (which also works well in IDH-mutant AML) should be first line remains debated; triplets are being tested.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
146 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survivalprimary | Ivosidenib + azacitidine | 72 | - | 0.33 (0.16 to 0.69) | 0.002 | link |
| Placebo + azacitidine | 74 | - | ||||
| Overall survival (median) | Ivosidenib + azacitidine | - | 24 months | 0.44 (0.27 to 0.73) | - | link |
| Placebo + azacitidine | - | 7.9 months | ||||
| Complete remission | Ivosidenib + azacitidine | - | 47% | - | - | link |
| Placebo + azacitidine | - | 15% |
Shares IDH inhibitors, Servier, Ivosidenib, Acute myeloid leukaemia in older or unfit patients.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, Ivosidenib, IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH inhibitors, IDH1- and IDH2-mutated acute myeloid leukaemia, IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Azacitidine.
Shares Courtney D. DiNardo, IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.